TI finds corruption in German pharma
The watchdog Transparency International (TI) has warned of the influence of the pharmaceutical industry on doctors and researchers in Germany, after revealing that corruption costs the German health care system somewhere between 8.0 million euros and 24.0 billion euros ($10.3 and $30.8 billion) annually.
In its annual report, the German arm of TI claims that the most serious corruption in the country's health care sector is the pharmaceutical industry's influence on licensing, medical and therapeutic assessment and marketing of products.
It claims that medical research is being faked, doctors are being paid to prescribe a company's drugs and firms are infiltrating self-help groups.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze